New Enterprise Associates

IonQ, Inc. specializes in the development of general-purpose quantum information computers, utilizing a unique trapped ion approach. The company's technology combines high physical performance, perfect qubit replication, and optical networkability, enabling the creation of scalable quantum computers that surpass the limitations of classical computing. These advancements leverage phenomena such as superposition and entanglement, which are critical at the atomic scale. Founded in 2015 and headquartered in College Park, Maryland, IonQ aims to support a wide range of applications across various industries with its powerful and versatile quantum computing solutions.

Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.

Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.

Resilience is a biopharmaceutical manufacturing and technology company based in La Jolla, California, established in 2020. It aims to enhance access to complex medicines and safeguard biopharmaceutical supply chains. The company specializes in end-to-end manufacturing and development solutions across various therapeutic modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. Resilience provides customized manufacturing capabilities that cater to the diverse needs of biopharmaceuticals at all stages of the drug development process, from pre-clinical development to commercial supply. With a focus on developing new manufacturing technologies, Resilience ensures high-quality and regulatory-compliant processes for complex and novel medicines.

ZeroFox is a cybersecurity company based in Baltimore, Maryland, that specializes in protecting organizations from threats arising from social networking and digital communication platforms. The company offers a range of solutions, including real-time social threat analytics, intelligence, and advanced security protection through its cloud-based platform. Its products, such as the ZeroFOX intelligence Livefeed and Protection Cloud, help organizations proactively defend against malware, targeted attacks, and various forms of social engineering, including impersonation and fraud. Additionally, ZeroFox provides services aimed at safeguarding high-value employees and political candidates from targeted threats. The company serves diverse industries, including financial services, healthcare, and technology, by continuously monitoring social media for cyber attacks and information loss. Founded in 2013, ZeroFox has received multiple industry accolades for its innovative approach to cybersecurity.

IonQ, Inc. specializes in the development of general-purpose quantum information computers, utilizing a unique trapped ion approach. The company's technology combines high physical performance, perfect qubit replication, and optical networkability, enabling the creation of scalable quantum computers that surpass the limitations of classical computing. These advancements leverage phenomena such as superposition and entanglement, which are critical at the atomic scale. Founded in 2015 and headquartered in College Park, Maryland, IonQ aims to support a wide range of applications across various industries with its powerful and versatile quantum computing solutions.

Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.

Framebridge, Inc. specializes in custom framing solutions for art and photographs, offering a streamlined online service that prioritizes customer experience. Founded in 2014 and based in Washington, D.C., the company allows users to select from a curated range of contemporary frame styles, upload images, or send physical items for personalized framing. The expert team at Framebridge handcrafts frames to meet each customer's specifications, ensuring high-quality results. Finished products are shipped directly to consumers, typically arriving within days and ready to hang. Pricing is transparent and based on the size of the framed item, starting at $39 and including free shipping. Framebridge operates manufacturing facilities in Richmond, Kentucky, and Lanham, Maryland, and has attracted investments from notable firms and individuals in the retail and technology sectors.

Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.

IONQ develops general-purpose quantum information processors to solve the world’s complex problems. Its unique trapped ion approach combines unmatched physical performance, perfect qubit replication, optical networkability, and highly optimized algorithms to create a quantum computer that is as scalable as it is powerful and that will support a broad array of applications across a variety of industries. It was founded in 2015 and is based in College Park, Maryland.

Framebridge, Inc. specializes in custom framing solutions for art and photographs, offering a streamlined online service that prioritizes customer experience. Founded in 2014 and based in Washington, D.C., the company allows users to select from a curated range of contemporary frame styles, upload images, or send physical items for personalized framing. The expert team at Framebridge handcrafts frames to meet each customer's specifications, ensuring high-quality results. Finished products are shipped directly to consumers, typically arriving within days and ready to hang. Pricing is transparent and based on the size of the framed item, starting at $39 and including free shipping. Framebridge operates manufacturing facilities in Richmond, Kentucky, and Lanham, Maryland, and has attracted investments from notable firms and individuals in the retail and technology sectors.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes, primarily in Europe. Founded in 1996, the company develops advanced implantable CGM products, including Eversense and Eversense XL, which monitor glucose levels for up to 90 and 180 days, respectively. Using innovative fluorescence sensing technology, these systems are designed to provide high accuracy and stability throughout their extended sensor life. The company aims to empower people with diabetes to manage their condition more effectively and confidently through its CGM solutions, which also include a smart transmitter and a mobile app. A significant portion of Senseonics' revenue is generated from markets outside the United States.

Blispay Inc. is a financial technology company based in Baltimore, Maryland, that specializes in providing mobile payment solutions and point-of-sale financing for small and midsize retailers. Founded in 2014, Blispay offers a mobile-centric credit card that allows merchants to provide financing options to their customers without the need for technical integration or financial obligations. The Blispay Visa Card features instant issuance, six months of special financing, and a cash-back incentive, making it an attractive option for both retailers and consumers. The company's founding team includes industry veterans with backgrounds from notable organizations, enhancing its capability to deliver innovative financial products that meet the needs of modern shoppers and merchants alike.

Fugue, Inc. is a company that specializes in cloud infrastructure automation and security software. Founded in 2012 and based in Frederick, Maryland, Fugue develops an operating system designed for managing cloud-based workloads. The company's solutions focus on ensuring continuous compliance with enterprise security policies by identifying and addressing security risks and compliance violations. Fugue's software features capabilities such as baseline drift detection, automated remediation, and powerful visualization and reporting tools, which help organizations demonstrate compliance with various frameworks, including HIPAA, GDPR, and NIST 800-53. It integrates with CI/CD pipelines to prevent unauthorized changes and automate compliance audits. Notable clients include Sparkpost, PBS, and SAP NS2, who rely on Fugue to mitigate cloud risks and enforce compliance effectively.

Vtesse, Inc. develops drugs for patients suffering from rare diseases. The company focuses on conducting the clinical study of VTS-270 for the treatment of Niemann-Pick disease type C (NPC), as well as on conducting pre-clinical discovery and development of other novel drugs for NPC and other lysosomal storage diseases. Vtesse, Inc. is based in Gaithersburg, Maryland. As of April 3, 2017, Vtesse, Inc. operates as a subsidiary of Sucampo Pharmaceuticals, Inc.

Framebridge, Inc. specializes in custom framing solutions for art and photographs, offering a streamlined online service that prioritizes customer experience. Founded in 2014 and based in Washington, D.C., the company allows users to select from a curated range of contemporary frame styles, upload images, or send physical items for personalized framing. The expert team at Framebridge handcrafts frames to meet each customer's specifications, ensuring high-quality results. Finished products are shipped directly to consumers, typically arriving within days and ready to hang. Pricing is transparent and based on the size of the framed item, starting at $39 and including free shipping. Framebridge operates manufacturing facilities in Richmond, Kentucky, and Lanham, Maryland, and has attracted investments from notable firms and individuals in the retail and technology sectors.

Blispay Inc. is a financial technology company based in Baltimore, Maryland, that specializes in providing mobile payment solutions and point-of-sale financing for small and midsize retailers. Founded in 2014, Blispay offers a mobile-centric credit card that allows merchants to provide financing options to their customers without the need for technical integration or financial obligations. The Blispay Visa Card features instant issuance, six months of special financing, and a cash-back incentive, making it an attractive option for both retailers and consumers. The company's founding team includes industry veterans with backgrounds from notable organizations, enhancing its capability to deliver innovative financial products that meet the needs of modern shoppers and merchants alike.

Fugue, Inc. is a company that specializes in cloud infrastructure automation and security software. Founded in 2012 and based in Frederick, Maryland, Fugue develops an operating system designed for managing cloud-based workloads. The company's solutions focus on ensuring continuous compliance with enterprise security policies by identifying and addressing security risks and compliance violations. Fugue's software features capabilities such as baseline drift detection, automated remediation, and powerful visualization and reporting tools, which help organizations demonstrate compliance with various frameworks, including HIPAA, GDPR, and NIST 800-53. It integrates with CI/CD pipelines to prevent unauthorized changes and automate compliance audits. Notable clients include Sparkpost, PBS, and SAP NS2, who rely on Fugue to mitigate cloud risks and enforce compliance effectively.

ZeroFox is a cybersecurity company based in Baltimore, Maryland, that specializes in protecting organizations from threats arising from social networking and digital communication platforms. The company offers a range of solutions, including real-time social threat analytics, intelligence, and advanced security protection through its cloud-based platform. Its products, such as the ZeroFOX intelligence Livefeed and Protection Cloud, help organizations proactively defend against malware, targeted attacks, and various forms of social engineering, including impersonation and fraud. Additionally, ZeroFox provides services aimed at safeguarding high-value employees and political candidates from targeted threats. The company serves diverse industries, including financial services, healthcare, and technology, by continuously monitoring social media for cyber attacks and information loss. Founded in 2013, ZeroFox has received multiple industry accolades for its innovative approach to cybersecurity.

Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.

Framebridge, Inc. specializes in custom framing solutions for art and photographs, offering a streamlined online service that prioritizes customer experience. Founded in 2014 and based in Washington, D.C., the company allows users to select from a curated range of contemporary frame styles, upload images, or send physical items for personalized framing. The expert team at Framebridge handcrafts frames to meet each customer's specifications, ensuring high-quality results. Finished products are shipped directly to consumers, typically arriving within days and ready to hang. Pricing is transparent and based on the size of the framed item, starting at $39 and including free shipping. Framebridge operates manufacturing facilities in Richmond, Kentucky, and Lanham, Maryland, and has attracted investments from notable firms and individuals in the retail and technology sectors.

Vtesse, Inc. develops drugs for patients suffering from rare diseases. The company focuses on conducting the clinical study of VTS-270 for the treatment of Niemann-Pick disease type C (NPC), as well as on conducting pre-clinical discovery and development of other novel drugs for NPC and other lysosomal storage diseases. Vtesse, Inc. is based in Gaithersburg, Maryland. As of April 3, 2017, Vtesse, Inc. operates as a subsidiary of Sucampo Pharmaceuticals, Inc.

Framebridge, Inc. specializes in custom framing solutions for art and photographs, offering a streamlined online service that prioritizes customer experience. Founded in 2014 and based in Washington, D.C., the company allows users to select from a curated range of contemporary frame styles, upload images, or send physical items for personalized framing. The expert team at Framebridge handcrafts frames to meet each customer's specifications, ensuring high-quality results. Finished products are shipped directly to consumers, typically arriving within days and ready to hang. Pricing is transparent and based on the size of the framed item, starting at $39 and including free shipping. Framebridge operates manufacturing facilities in Richmond, Kentucky, and Lanham, Maryland, and has attracted investments from notable firms and individuals in the retail and technology sectors.

Fugue, Inc. is a company that specializes in cloud infrastructure automation and security software. Founded in 2012 and based in Frederick, Maryland, Fugue develops an operating system designed for managing cloud-based workloads. The company's solutions focus on ensuring continuous compliance with enterprise security policies by identifying and addressing security risks and compliance violations. Fugue's software features capabilities such as baseline drift detection, automated remediation, and powerful visualization and reporting tools, which help organizations demonstrate compliance with various frameworks, including HIPAA, GDPR, and NIST 800-53. It integrates with CI/CD pipelines to prevent unauthorized changes and automate compliance audits. Notable clients include Sparkpost, PBS, and SAP NS2, who rely on Fugue to mitigate cloud risks and enforce compliance effectively.

Framebridge, Inc. specializes in custom framing solutions for art and photographs, offering a streamlined online service that prioritizes customer experience. Founded in 2014 and based in Washington, D.C., the company allows users to select from a curated range of contemporary frame styles, upload images, or send physical items for personalized framing. The expert team at Framebridge handcrafts frames to meet each customer's specifications, ensuring high-quality results. Finished products are shipped directly to consumers, typically arriving within days and ready to hang. Pricing is transparent and based on the size of the framed item, starting at $39 and including free shipping. Framebridge operates manufacturing facilities in Richmond, Kentucky, and Lanham, Maryland, and has attracted investments from notable firms and individuals in the retail and technology sectors.

Cerecor Inc. is a biopharmaceutical company dedicated to the development and commercialization of treatments for rare pediatric and orphan diseases, with a particular focus on inherited metabolic disorders. The company's pipeline includes therapies such as CERC-801, CERC-802, and CERC-803, which have completed phase I clinical trials. Additionally, Cerecor is developing CERC-007, an anti-IL-18 monoclonal antibody for autoimmune inflammatory diseases, and CERC-006, a dual mTOR inhibitor for complex lymphatic malformations. Other notable developments include CERC-002 for pediatric-onset Crohn's disease, CERC-913 for mitochondrial disorders, and CERC-005 for rare auto-inflammatory diseases. Cerecor also offers Millipred, an oral prednisolone for various inflammatory conditions. Founded in 2011 and headquartered in Rockville, Maryland, the company was previously known as Ceregen Corporation before rebranding in March 2011.

NexImmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, that specializes in developing innovative immuno-therapeutics using its proprietary Artificial Immune (AIM) technology. Founded in 2011, the company focuses on orchestrating specific immune responses to treat various conditions, including cancer, inflammation, viral diseases, transplant rejection, and autoimmunity. NexImmune's lead products include AIM101, an injectable therapy targeting specific solid tumors, and AIM ACT, an adoptive cellular therapy aimed at treating specific hematological malignancies. The company is currently advancing two product candidates in clinical trials: NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma, both designed to harness the body's T cells for a targeted immune response with potential curative effects.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes, primarily in Europe. Founded in 1996, the company develops advanced implantable CGM products, including Eversense and Eversense XL, which monitor glucose levels for up to 90 and 180 days, respectively. Using innovative fluorescence sensing technology, these systems are designed to provide high accuracy and stability throughout their extended sensor life. The company aims to empower people with diabetes to manage their condition more effectively and confidently through its CGM solutions, which also include a smart transmitter and a mobile app. A significant portion of Senseonics' revenue is generated from markets outside the United States.

ZeroFox is a cybersecurity company based in Baltimore, Maryland, that specializes in protecting organizations from threats arising from social networking and digital communication platforms. The company offers a range of solutions, including real-time social threat analytics, intelligence, and advanced security protection through its cloud-based platform. Its products, such as the ZeroFOX intelligence Livefeed and Protection Cloud, help organizations proactively defend against malware, targeted attacks, and various forms of social engineering, including impersonation and fraud. Additionally, ZeroFox provides services aimed at safeguarding high-value employees and political candidates from targeted threats. The company serves diverse industries, including financial services, healthcare, and technology, by continuously monitoring social media for cyber attacks and information loss. Founded in 2013, ZeroFox has received multiple industry accolades for its innovative approach to cybersecurity.

Videology is a digital media advertising technology provider that specializes in connecting brands with consumers through targeted advertising solutions. The company leverages consumer data and advanced ad decisioning to enhance accountability and optimize the performance of video and display advertising campaigns. By offering a unified platform for managing and measuring video ad strategies across various screens, Videology ensures a more relevant and engaging experience for consumers who encounter its advertisements.

Traitify is a personality data company building the personality data genome for the employment marketplace. The company uses human interaction with images to create the fastest validated talent assessments in the market. Its platform includes the fastest talent assessments in the world multiple image-based behavioral assessments that are scientifically-validated and take 90 seconds to 2 minutes to complete on a mobile device and have 95% or greater completion rates. Companies use their platform to create a great candidate and employee experiences. Imagine giving value back to the candidates in the talent pool by making personalized recommendations for what job to apply for. Or generating personalized content to share back with candidates to create ongoing engagement, all based on their unique personality traits. Companies with great employment brands create reciprocity with candidates and employees alike.

Bravo Health, Inc. provides managed care services. It offers Medicare advantage options to allow members to choose the right plan for them; and special needs plans for those who are receiving institutional care, who have chronic health conditions, or who are eligible for both Medicare and Medicaid benefits. The company also provides private fee-for-service plans, which provide members the freedom to determine from whom they receive their health care; and part D prescription plans for those who only need coverage for their medications. It offers its plans to members in Delaware, Maryland, Pennsylvania, Texas, Washington, D.C., California, Florida, Illinois, Michigan, New Jersey, New York, Ohio, and West Virginia. Bravo Health, Inc. was formerly known as Elder Health, Inc. The company was founded in 1996 and is based in Baltimore, Maryland.

Sonatype, Inc. is a provider of software supply chain automation solutions aimed at enhancing software innovation, quality, and security. Established in 2008 and based in Fulton, Maryland, with additional offices in McLean, Virginia; London, United Kingdom; and Sydney, Australia, the company offers a range of products including Nexus Lifecycle, which manages the flow of software components, and Nexus Firewall, designed to prevent risky components from entering the supply chain. Its Nexus Auditor continuously monitors applications in production, while Nexus Repository organizes, stores, and distributes software components. Sonatype also supports the open-source community, having been a core contributor to Apache Maven and facilitating access to the largest repository of open source components. The company serves various industries, including finance, government, technology, insurance, healthcare, and manufacturing, and maintains strategic partnerships to enhance its offerings.

Videology is a digital media advertising technology provider that specializes in connecting brands with consumers through targeted advertising solutions. The company leverages consumer data and advanced ad decisioning to enhance accountability and optimize the performance of video and display advertising campaigns. By offering a unified platform for managing and measuring video ad strategies across various screens, Videology ensures a more relevant and engaging experience for consumers who encounter its advertisements.

Millennial Media Inc. specializes in mobile advertising solutions for advertisers and developers both in the United States and internationally. The company provides a platform that enables advertisers to reach targeted audiences across various mobile devices, offering tools to manage and analyze campaign performance. Key offerings include a demand side platform that connects advertisers directly to inventory, a premium mobile advertising exchange, and tools for creating ad content. For developers, Millennial Media supplies software development kits that facilitate different ad formats, along with mediation tools, ad serving capabilities, and detailed analytics on ad revenue. Additionally, its proprietary technology, MYDAS, identifies unique users and targets ads based on interests, behaviors, and locations. Founded in 2006 and headquartered in Baltimore, Maryland, Millennial Media has positioned itself as a significant player in the mobile advertising landscape, enhancing AOL's mobile capabilities following its acquisition.

Zyngenia, Inc. is a privately held biotherapeutics company established in 2008 that specializes in developing next-generation antibody-derived drugs. The company utilizes proprietary technology to create unique molecular entities, known as Zybody™, which combine the therapeutic activities of multiple biologic treatments into a single protein. This innovative approach allows Zyngenia to target complex diseases, particularly cancer and autoimmune disorders, by simultaneously addressing multiple biological pathways. By doing so, Zyngenia aims to facilitate quicker patient treatment initiation and improve overall clinical outcomes.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Millennial Media Inc. specializes in mobile advertising solutions for advertisers and developers both in the United States and internationally. The company provides a platform that enables advertisers to reach targeted audiences across various mobile devices, offering tools to manage and analyze campaign performance. Key offerings include a demand side platform that connects advertisers directly to inventory, a premium mobile advertising exchange, and tools for creating ad content. For developers, Millennial Media supplies software development kits that facilitate different ad formats, along with mediation tools, ad serving capabilities, and detailed analytics on ad revenue. Additionally, its proprietary technology, MYDAS, identifies unique users and targets ads based on interests, behaviors, and locations. Founded in 2006 and headquartered in Baltimore, Maryland, Millennial Media has positioned itself as a significant player in the mobile advertising landscape, enhancing AOL's mobile capabilities following its acquisition.

Availink (中天联科) is a company focused on designing chips using semiconductors for digital TV and multimedia areas, and developing application systems. Its product line extends to every specified market ranging from satellite television demodulator chips, to the fields of digital TV. The satellite television demodulator chip, covers all digital television technology standards such as satellites, ground surfaces, and wired. Availink provides many kinds of demodulation and decoding chips. The chip-based system platform schemes and multimedia solutions can mainly be applied to the rapidly developing digital TV field while providing products and services for global enterprise clients. Established in 2005, Availink was founded by a team of scientists. Currently It has a professional core management team with years of R&D experience. Availinks' accumulated chips shipped more than one hundred million pieces.

Optinuity, Inc. provides autonomic policy management solutions to enterprises and service providers. Its solutions include Optinuity Oasis, which provides software for creating and implementing autonomic policies to make complex business systems self-managed. The company also provides professional services, including autonomic policy planning and design, installation and configuration, and custom development services; and training services. It primarily offers its solutions for financial services, health care, and telecommunications sectors. Optinuity, Inc. was founded in 2004 and is headquartered in Bethesda, Maryland. As of October 6, 2008, Optinuity, Inc. operates as a subsidiary of CA, Inc.

Videology is a digital media advertising technology provider that specializes in connecting brands with consumers through targeted advertising solutions. The company leverages consumer data and advanced ad decisioning to enhance accountability and optimize the performance of video and display advertising campaigns. By offering a unified platform for managing and measuring video ad strategies across various screens, Videology ensures a more relevant and engaging experience for consumers who encounter its advertisements.

Hillcrest Laboratories, Inc. is a leading provider of software, components, and intellectual property focused on the intelligent integration of sensors in consumer electronics, robotics, and IoT devices. The company specializes in sensor fusion technology, transforming human and machine movements into actionable data that enhances product precision across various applications. Its key offerings include the FSP200 processor for robotic navigation, the BNO080/085 system in package for sensor-enabled AR and VR devices, and the FSM300 inertial measurement unit. Hillcrest's technology is utilized in products such as robotic cleaners, handheld motion controllers, and attitude monitoring systems. The company has established strategic relationships with major players in the Smart TV sector, including LG, Roku, and TCL, and has expanded its focus to include the smartphone and gaming industries. Founded in 2001 and based in Rockville, Maryland, Hillcrest Labs has received multiple awards for its innovations and operates as a subsidiary of CEVA, Inc.

Optinuity, Inc. provides autonomic policy management solutions to enterprises and service providers. Its solutions include Optinuity Oasis, which provides software for creating and implementing autonomic policies to make complex business systems self-managed. The company also provides professional services, including autonomic policy planning and design, installation and configuration, and custom development services; and training services. It primarily offers its solutions for financial services, health care, and telecommunications sectors. Optinuity, Inc. was founded in 2004 and is headquartered in Bethesda, Maryland. As of October 6, 2008, Optinuity, Inc. operates as a subsidiary of CA, Inc.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

CoGenesys is a biopharmaceutical company focused on the development of peptide- and protein-based medicines. The company develops peptide and protein-based medicines for cancer, cardiovascular, metabolic, infectious, autoimmune, and CNS diseases.

Sourcefire, Inc. specializes in enterprise threat management solutions for a variety of sectors, including healthcare, finance, manufacturing, energy, education, retail, telecommunications, and government organizations. The company is known for its open source and commercial security products, most notably Snort, which is an open source intrusion prevention technology integral to the Sourcefire 3D System. This system offers a comprehensive approach to network defense, combining intrusion prevention, network behavior analysis, access control, and vulnerability assessment within a unified management framework. Additionally, Sourcefire provides ClamAV, an open source gateway anti-virus and anti-malware solution. The company offers various technical support and professional services, including deployment assistance, customer support, and education. Sourcefire markets its products and services through both direct sales and partnerships with resellers, distributors, and original equipment manufacturers. Founded in 2001, Sourcefire is headquartered in Columbia, Maryland.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company’s extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization, then as a U.S. subsidiary of Shire plc and, upon its acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy, ADHD and depression. In addition to its two ADHD product candidates, Supernus is developing two late stage epilepsy product candidates, SPN-538 (extended release topiramate), and Epliga® (extended release oxcarbazepine).

Availink (中天联科) is a company focused on designing chips using semiconductors for digital TV and multimedia areas, and developing application systems. Its product line extends to every specified market ranging from satellite television demodulator chips, to the fields of digital TV. The satellite television demodulator chip, covers all digital television technology standards such as satellites, ground surfaces, and wired. Availink provides many kinds of demodulation and decoding chips. The chip-based system platform schemes and multimedia solutions can mainly be applied to the rapidly developing digital TV field while providing products and services for global enterprise clients. Established in 2005, Availink was founded by a team of scientists. Currently It has a professional core management team with years of R&D experience. Availinks' accumulated chips shipped more than one hundred million pieces.

eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.

Availink (中天联科) is a company focused on designing chips using semiconductors for digital TV and multimedia areas, and developing application systems. Its product line extends to every specified market ranging from satellite television demodulator chips, to the fields of digital TV. The satellite television demodulator chip, covers all digital television technology standards such as satellites, ground surfaces, and wired. Availink provides many kinds of demodulation and decoding chips. The chip-based system platform schemes and multimedia solutions can mainly be applied to the rapidly developing digital TV field while providing products and services for global enterprise clients. Established in 2005, Availink was founded by a team of scientists. Currently It has a professional core management team with years of R&D experience. Availinks' accumulated chips shipped more than one hundred million pieces.

Optinuity, Inc. provides autonomic policy management solutions to enterprises and service providers. Its solutions include Optinuity Oasis, which provides software for creating and implementing autonomic policies to make complex business systems self-managed. The company also provides professional services, including autonomic policy planning and design, installation and configuration, and custom development services; and training services. It primarily offers its solutions for financial services, health care, and telecommunications sectors. Optinuity, Inc. was founded in 2004 and is headquartered in Bethesda, Maryland. As of October 6, 2008, Optinuity, Inc. operates as a subsidiary of CA, Inc.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Psyadon Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for serious psychiatric and neurological diseases. Founded in 2004 and based in Germantown, Maryland, the company specializes in creating medicinal drugs, particularly Ecopipam, which selectively blocks the actions of the neurotransmitter dopamine at the D1 subtype in the brain. This targeted approach aims to provide therapeutic options for patients who have limited alternatives. Formerly known as Ruxton Pharmaceuticals, Inc., Psyadon Pharmaceuticals rebranded in October 2008 and operates as a subsidiary of Emalex Biosciences, Inc.

Sourcefire, Inc. specializes in enterprise threat management solutions for a variety of sectors, including healthcare, finance, manufacturing, energy, education, retail, telecommunications, and government organizations. The company is known for its open source and commercial security products, most notably Snort, which is an open source intrusion prevention technology integral to the Sourcefire 3D System. This system offers a comprehensive approach to network defense, combining intrusion prevention, network behavior analysis, access control, and vulnerability assessment within a unified management framework. Additionally, Sourcefire provides ClamAV, an open source gateway anti-virus and anti-malware solution. The company offers various technical support and professional services, including deployment assistance, customer support, and education. Sourcefire markets its products and services through both direct sales and partnerships with resellers, distributors, and original equipment manufacturers. Founded in 2001, Sourcefire is headquartered in Columbia, Maryland.

Hillcrest Laboratories, Inc. is a leading provider of software, components, and intellectual property focused on the intelligent integration of sensors in consumer electronics, robotics, and IoT devices. The company specializes in sensor fusion technology, transforming human and machine movements into actionable data that enhances product precision across various applications. Its key offerings include the FSP200 processor for robotic navigation, the BNO080/085 system in package for sensor-enabled AR and VR devices, and the FSM300 inertial measurement unit. Hillcrest's technology is utilized in products such as robotic cleaners, handheld motion controllers, and attitude monitoring systems. The company has established strategic relationships with major players in the Smart TV sector, including LG, Roku, and TCL, and has expanded its focus to include the smartphone and gaming industries. Founded in 2001 and based in Rockville, Maryland, Hillcrest Labs has received multiple awards for its innovations and operates as a subsidiary of CEVA, Inc.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Covega Corporation specializes in the development of optoelectronic components and subsystems, utilizing proprietary technologies in Indium Phosphide (InP) and Lithium Niobate (LiNbO3) to produce high-performance optical devices and modules. The company offers a range of products, including superluminescent diodes, semiconductor optical amplifiers, Fabry Perot lasers, gain chips, broad area lasers, and various types of modulators. Initially focused on the telecommunications, datacom, and CATV sectors, Covega has diversified its revenue streams and now derives over one-third of its income from the defense, medical, industrial, and instrumentation markets. By providing vertically integrated capabilities and foundry services, Covega meets the diverse needs of its clients across multiple industries with innovative and cost-effective solutions.

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was incorporated in 1997 and is based in Gaithersburg, Maryland. Intercell USA, Inc. was formerly known as Iomai Corporation. As a result of the acquisition of Iomai Corporation by Intercell Ag, Iomai Corporation's name was changed. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Intercell Biomedical Research & Development AG.

eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.

Megisto Systems specializes in the development of hardware and software solutions for telecom companies. The company provides a software-based subscriber services switch known as MSDS, which facilitates real-time prepaid and event-based charging, as well as subscriber service control. This technology enables mobile wireless and networking companies to enhance their service offerings, delivering profitable and personalized experiences to mobile data subscribers. Additionally, Megisto's hardware connects mobile wireless subscribers to various data services, supporting the infrastructure necessary for effective telecommunications.

CODEON Corporation designs and manufactures state-of-the-art optical components for the fiber optic telecommunications industry.

YAFO Networks designs, manufacturers and markets optical-electrical hardware subsystems for fiber optic networks. YAFO’s goal is clear - provide high quality, cutting-edge photonic network sub-system level solutions. By employing the highest caliber of talent in the fiber optics and communications industries, They specialize in Their ability to identify and target key optical transport problems, and incorporate the technologies that best solve these problems. This provides YAFO’s customers with the advantage of having access to the highest quality of optical communication solutions with fastest time to market. YAFO’s innovative solutions drive down the equipment cost of transporting data while greatly enhancing the quality of bit.

AMISYS Managed Care Systems, Inc. develops, markets and supports managed health care information systems and software.

Genetic Therapy develops products and services based on proprietary technology to implement human gene therapy.

Bethesda Research Laboratories is a developer and distributor of enzymes and other products allowing manipulation of DNA.